Novo Nordisk saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month https://t.co/18aNVE0tWf ...

Gilead said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs https://t.co/VqTjk0MPkh ...

Today in Bloomberg Deals: South Korea is drawing in beauty deals, plus Li Ka-shing eyes more telco sales and Italian drugmaker Angelini Pharma has agreed to buy Catalyst Pharmaceuticals for $4.1 billion. https://t.co/IfrokEf7vW ...

Eli Lilly’s blockbuster diabetes drug Mounjaro has surpassed Merck’s cancer therapy Keytruda as the world’s best-selling medication https://t.co/dYIeDbXsBz ...

Eli Lilly is spending another $4.5 billion on its manufacturing plants in Indiana as the pharmaceutical company shores up its domestic supply chain. https://t.co/0Kpx54TUjD ...

So, Albert, thank you so much for joining us on this very special day for you at Pfizer. You had your first quarter results out, which were strong and beat estimates. As you look at those results.Why do you think you beat the estimates and what does it tell you about the rest of the year. Well, it's about execution. We were very focused and our commercial investing, which is basically the reflection of these commercial results, is one of a kind.They are very, very good. They understand the customer. They un ...

We were reviewing with our board uh the first molecule that we were able to completely design through AI just two weeks ago and uh 3 months ago we wouldn't be able to do it and 3 months later we have already a molecule already designed right in the face but also I want to say that when it speaks about AI there are two different uh areas one it is what technology can do now and cannot do everything But clearly can do much more than we are using to. And the bottleneck for something like that is not technologi ...

I'LL SEND IT BACK TO YOU. >> IT'S INTERESTING. HE ACTUALLY THINKS THE BID MIGHT BE REAL.IT'S NOT SURPRISING. ALL RIGHT. THANK YOU.CONTESSA. THE FDA HAS BEEN UNDER FIRE RECENTLY. PATIENTS, ONCOLOGISTS AND BIOTECH INVESTORS HAVE BEEN PRESSING COMMISSIONER DOHERTY MCCAREY OVER A STRING OF DRUG REJECTIONS, NONE MORE CONTENTIOUS THAN REPLIMUNE.THAT'S A HAS A CANCER THERAPY FOR MELANOMA PATIENTS THAT BACKERS SAY PUTS A THIRD OF PATIENTS INTO MULTI-YEAR REMISSIONS. AND THE ORIGINAL REVIEW TEAM AT THE FDA DID SEEM ...

BioNTech plans to halt operations at several manufacturing sites, affecting as many as 1,860 jobs, due to dwindling demand for its Covid-19 vaccine https://t.co/2CsN8xq9F7 ...

Pfizer reports first quarter sales that beat estimates as demand for older blockbusters helped to offset a decline in revenues from Covid products https://t.co/p6yEwSalas ...